Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica.

Literature DB >> 17917332

Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica.

Kazumasa Okada¹, Sadatoshi Tsuji, Keiko Tanaka.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2007 PMID： 17917332 DOI： 10.2169/internalmedicine.46.0217

Source DB: PubMed Journal: Intern Med ISSN： 0918-2918 Impact factor: 1.271

Keyword Cloud
Cited

× No keyword cloud information.

21 in total

Review 1. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors: M Stangel; R Gold
Journal: Nervenarzt Date: 2011-04 Impact factor: 1.214

2. Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.

Authors: Sho Nobuyoshi; Akiyasu Kanamori; Yoshiko Matsumoto; Makoto Nakamura
Journal: Jpn J Ophthalmol Date: 2016-06-07 Impact factor: 2.447

3. [Therapeutic options for autoimmune encephalomyelitis].

Authors: N Borisow; H Prüss; F Paul
Journal: Nervenarzt Date: 2013-04 Impact factor: 1.214

4. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Authors: Julien Ratelade; Alex J Smith; A S Verkman
Journal: Exp Neurol Date: 2014-03-14 Impact factor: 5.330

Review 5. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors: Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal: Nat Rev Neurol Date: 2014-08-12 Impact factor: 42.937

6. Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors: Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal: Mult Scler Relat Disord Date: 2012-10 Impact factor: 4.339

Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica.

Review 1. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

2. Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.

3. [Therapeutic options for autoimmune encephalomyelitis].

4. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Review 5. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

6. Treatment of Neuromyelitis Optica: Review and Recommendations.

Review 7. Neuromyelitis optica: potential roles for intravenous immunoglobulin.

8. Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.

9. [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Review 10. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.